Letter: mesalazine—a safe drug with rare serious adverse events? Authors’ reply

Abstract

LINKED CONTENT This article is linked to Sehgal et al and Scrivo et al papers. To view these articles, visit https://doi.org/10.1111/apt.14688 and https://doi.org/10.1111/apt.15691.